Geschäftsführung und Leitung der IOZK Arbeitsgruppe
Die Vision des IOZK: Immun-onkologische Forschungserkenntnisse zeitnah in die Praxis umzusetzen
Dr. Wilfried Stücker ist Geschäftsführer des IOZK und der IOZK Stiftung. 1985 hat er das heutige Immun-Onkologische Zentrum Köln initiiert. In Zusammenarbeit mit verschiedenen Ärzten und Wissenschaftlern entwickelte er die IOZK-Immuntherapie und baute das Behandlungszentrum mit den Laboratorien auf.
Die IOZK Stiftung wurde 2019 zur Optimierung von Immuntherapien gegen Krebs gegründet.
„Das Leben der Krebspatienten zu verlängern und Ihnen eine schonende Therapie anzubieten, dafür setzen wir uns am IOZK mit unserer Expertise ein.“
Dr. Wilfried Stücker
Sammlung: Wissenschaftliche Beiträge und internationale Publikationen von Dr. Wilfried Stücker
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-06-23 / Biomedicines 2023 Jun;11(7)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-06-23 / Biomedicines 2023 Jun;11(7)2023-06-23 00:00:002024-04-17 15:04:06The Application of Evidence-Based Medicine in Individualized Medicine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-02-13 / Cancers (Basel) 2023 Feb;15(4)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002022-02-28 / Biomedicines 2022 Feb;10(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002025-03-27 05:35:20Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002021-07-04 / Cancer Immunol Immunother 2021 Jul;https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-05-19 / Medicines (Basel) 2020 May;7(5)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-08-30 / Biomedicines 2019 Aug;7(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002015-05-28 / Immunotherapy 2015;7(8):855-60https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-24062014-10-06 00:00:002021-11-16 07:53:33Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report